Skip to content

Bevacizumab+folfiri in untreated patients with advanced colorectal cancer. A phase II multicenter study of the Gruppo Oncologico dell'Italia Meridionale. (GOIM). - Bevacizumab+folfiri in untreated patients with advanced colorectal cance

Bevacizumab+folfiri in untreated patients with advanced colorectal cancer. A phase II multicenter study of the Gruppo Oncologico dell'Italia Meridionale. (GOIM). - Bevacizumab+folfiri in untreated patients with advanced colorectal cance

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-002887-25-IT
Enrollment
Unknown
Registered
2007-06-26
Start date
2006-06-27
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

untreated patients with advanced colorectal cancer. MedDRA version: 9.1 Level: LLT Classification code 10010035 Term: Colorectal cancer stage IV

Interventions

Sponsors

GOIM GRUPPO ONCOLOGICO MERIDIONALE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Locally advanced or metastatic non-resectable colorectal cancer Histologically confirmed adenocarcinoma Presence of at least one measurable lesion Age >= 18 years and 70 at study entry Life expectancy of > 3 months Laboratory data: Neutrophils >= 1.5 x 109/L, platelets >= 100 x 109/L, hemoglobin >= 9 g/dl ALAT and ASAT =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Brain metastasis Previous chemotherapy for locally advanced or metastatic colorectal (adjuvant therapy without irinotecan is allowed if recurrence is documented > 6 months after the end of adjuvant treatment) Radiotherapy within 4 weeks prior to study entry Clinically relevant coronary artery disease or history of a myocardial infarction within the last 12 months Acute or subacute intestinal occlusion or history of the inflammatory bowel disease Patients with peripheral neuropathy (NCI CTC >1) Known drug abuse/alcohol Legal incapacity or limited legal capacity Medical or psychological condition which, in the opinion of the investigator, would not enable the patient to complete the study or knowingly sign the Informed Consent Women who are pregnant or breastfeeding Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix (patients with a previous malignancy but with no evidence of disease for > 5 years will be allowed to enter the trial)

Design outcomes

Primary

MeasureTime frame
Main Objective: Objectively confirmed response rate Time-to- progression;Secondary Objective: Safety of combination Median response duration Overall survival time Post-treatment resectability of lung/liver metastases;Primary end point(s): Objectively confirmed response rate Time-to- progression

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026